{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:40:03Z","timestamp":1761831603035,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jacl.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:13:24Z","timestamp":1594815204000},"page":"639-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature"],"prefix":"10.1016","volume":"14","author":[{"given":"Aravind Venkatesh","family":"Sreedharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon Li Ting","family":"Pek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng Hong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Tavintharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jacl.2020.07.006_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.jacl.2020.07.006_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"45","key":"10.1016\/j.jacl.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype\u2013phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/CIRCGENETICS.116.001545","article-title":"Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship","volume":"9","author":"Sanchez-Hernandez","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CEOR.S43087","article-title":"Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey","volume":"5","author":"Walzer","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.jacl.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.amjcard.2016.11.025","article-title":"Value of the definition of severe familial hypercholesterolemia for stratification of heterozygous patients","volume":"119","author":"Perez-Calahorra","year":"2017","journal-title":"Am J Cardiol"},{"issue":"32","key":"10.1016\/j.jacl.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"9965","key":"10.1016\/j.jacl.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2008.11.029","article-title":"Echocardiographic assessment of valve stenosis: EAE\/ASE recommendations for clinical practice","volume":"22","author":"Baumgartner","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacl.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2017.12.028","article-title":"Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: single center study","volume":"269","author":"Pek","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"17272","DOI":"10.1038\/srep17272","article-title":"The distribution and characteristics of LDL receptor mutations in China: a systematic review","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jacl.2020.07.006_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3476(05)83444-4","article-title":"Use of cholestyramine in the treatment of children with familial combined hyperlipidemia","volume":"122","author":"Liacouras","year":"1993","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jacl.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.jacl.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2020.07.006_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1542\/peds.89.3.495","article-title":"Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents","volume":"89","year":"1992","journal-title":"Pediatrics"},{"issue":"1 Pt 1","key":"10.1016\/j.jacl.2020.07.006_bib18","first-page":"141","article-title":"Committee on Nutrition. Cholesterol in childhood","volume":"101","year":"1998","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.jacl.2020.07.006_bib19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/hrt.80.6.583","article-title":"Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia","volume":"80","author":"Rallidis","year":"1998","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.jacl.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"17","key":"10.1016\/j.jacl.2020.07.006_bib22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","author":"de Jongh","year":"2002","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacl.2020.07.006_bib23","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2020.07.006_bib24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jacl.2020.07.006_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.jacl.2020.07.006_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacl.2020.07.006_bib27","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.jacl.2020.07.006_bib28","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.2169\/internalmedicine.1060-18","article-title":"Coronary artery plaque regression by a PCSK9 antibody and rosuvastatin in double-heterozygous familial hypercholesterolemia with an ldl receptor mutation and a PCSK9 V4I mutation","volume":"57","author":"Shirahama","year":"2018","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.jacl.2020.07.006_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jacl.2020.07.006_bib30","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacl.2020.07.006_bib31","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2020.07.006_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jacl.2020.07.006_bib33","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2020.07.006_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2020.07.006_bib35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2020.07.006_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jacl.2018.10.011","article-title":"Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: a systematic review","volume":"13","author":"Luirink","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2020.07.006_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2020.07.006_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","article-title":"Recent developments in gene therapy for homozygous familial hypercholesterolemia","volume":"18","author":"Ajufo","year":"2016","journal-title":"Curr Atheroscler Rep"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420302166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420302166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:35:57Z","timestamp":1761831357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420302166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1933287420302166"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.07.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}